VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

VBL Ther­a­peu­tics an­nounced that it is on track in a Phase III tri­al of its drug VB-111 (ofran­er­gene obade­n­ovec) to treat …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.